NASDAQ: $CTOR Citius Oncology, Inc., a key player in oncology biopharmaceuticals and a subsidiary of Citius Pharmaceuticals, Inc., recently shared encouraging topline safety and efficacy results from an investigator-initiated Phase 1 trial. This study explored the utility of LYMPHIR™ (E7777, denileukin diftitox?cxdl) when administered as a preparatory treatment before commercial CD19-directed CAR-T cell therapy for…